Synthetic therapeutic microbes for tailored antimicrobial therapies (SynThera)

Antibiotic-resistant bacteria are becoming increasingly common. In addition, conventional antibiotics also harm the beneficial human microbiome and lead to complex side effects. The "antibiotic crisis" poses a significant threat to modern medicine and a major challenge to global public health. Tackling this crisis requires innovative approaches that go beyond conventional antibiotic development. In order to develop new treatment approaches for multi-resistant bacteria, the "SynThera" project relies on interdisciplinary approaches from the field of synthetic biology. The development of therapeutic microorganisms is intended to combat multi-resistant pathogens in a targeted manner and directly at the site of infection. With these customized solutions, "SynThera" aims to fundamentally change antimicrobial therapies. The research team consists of scientists from Friedrich Schilller University Jena and the Leibniz Institute for Natural Product Research and Infection Biology - Hans Knöll Institute (HKI) Jena.